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Objective: To explore associations between remission, based on clinical and ultrasound 
definitions, and future good radiographic and physical outcome in early rheumatoid arthritis 
(RA).  
 
Methods: Newly diagnosed RA patients followed a treat-to-target strategy incorporating 
ultrasound information in the ARCTIC-trial. We defined 6-month remission according to 
DAS, DAS28-ESR, ACR/EULAR Boolean criteria, SDAI, CDAI and two ultrasound 
definitions (no power Doppler signal, grey scale score ≤2). Two outcomes were defined; no 
radiographic progression and good outcome (no radiographic progression + physical function 
≥ general population median), both sustained 12-24 months. We calculated the odds ratios 
(OR) of these outcomes for the remission definitions.  
 
Results: Of 103 patients, 42-82% reached remission at 6 months, dependent on definition. 
71% of patients had no radiographic progression and 37% good outcome. An association 
between 6-month remission and no radiographic progression was observed for ACR/EULAR 
Boolean remission (44 joints, OR 3.2 CI 1.2 to 8.4), ultrasound power Doppler (OR 3.6 CI 1.3 
to 10.0) and grey scale remission (OR 3.2 CI 1.2 to 8.0). All clinical, but not ultrasound 
remission criteria were associated with achievement of a good outcome.  
 
Conclusions: Our data support ACR/EULAR Boolean remission based on 44 joints as the 
preferred treatment target in early RA. Absence of ultrasound inflammation was associated 
with no radiographic progression.  
 
KEYWORDS: Early Rheumatoid Arthritis, Disease Activity, Outcome research, 
Ultrasonography   
INTRODUCTION 
Early initiation of disease-modifying anti-rheumatic drug (DMARD) therapy with a defined 
treatment target within 6 months has become a keystone in the management of patients with 
rheumatoid arthritis (RA).[1, 2] Prevention of joint damage and disability are now achievable 
outcomes for a large proportion of newly diagnosed RA patients.[3]  
Composite scores such as the Disease Activity Score (DAS), Disease Activity Score in 28 
joints (DAS28), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity 
Index (CDAI) are used to measure disease activity and guide therapeutic decisions.[1, 4-6] 
Additionally, the Boolean based American College of Rheumatology (ACR)/European 
League Against Rheumatism (EULAR) remission criterion was developed to optimize 
radiographic and functional outcomes.[7] The ACR/EULAR task force recommended 
inclusion of ankles and forefeet in the assessment of remission, although formally not 
required.[7]  
Remission according to composite scores and Boolean based criteria is associated with less 
radiographic joint damage,[7-9] and remission should be sustained as radiographic 
progression is a consequence of cumulative inflammation.[10-12] However, not all patients 
fulfilling clinical remission criteria show absence of radiographic progression, and ongoing 
subclinical inflammation detected by ultrasonography and magnetic resonance imaging may 
explain this discrepancy.[13]   
The aim of this study was to explore the association between remission at 6 months and two 
outcomes of importance for evaluation of treatment success, 1) future no radiographic 
progression and 2) a combined good outcome of no radiographic progression and physical 
function comparable to the general population. In particular, we wanted to assess how 
potential ultrasound definitions of remission performed in comparison to clinical definitions.   
METHODS 
Patients and study design 
DMARD-naïve early RA patients fulfilling the 2010 ACR/EULAR criteria were enrolled in 
the ARCTIC trial, randomising patients to a conventional or ultrasound tight control 
strategy.[14] Only patients with ultrasound examinations at all visits (ultrasound strategy, 
N=118) were included in the current analyses to allow for assessment of potential ultrasound 
definitions of remission. Patients without two radiographs during the second year of the study 
were excluded (N=15). Patients attended 13 visits in two years with treatment adjustments 
according to an algorithm targeting clinical remission (DAS<1.6), no swollen joints, and 
absence of ultrasound power Doppler signal (Table S1). Ultrasound examination of 32 joints 
was performed by trained physicians with semi-quantitative 0-3 scoring of synovitis for grey 
scale and power Doppler.[14, 15] Patients were started on methotrexate with prednisolone 
bridging (Table S1). Therapy was escalated if the target was not reached, patients with high 
disease activity and risk factors for progressive joint destruction could start biologics more 
rapidly (Table S1). The study was conducted in compliance with the Declaration of Helsinki.  
 
Definitions of remission  
Four clinical composite remission criteria were assessed: DAS, DAS28-erythrocyte 
sedimentation rate (ESR), CDAI and SDAI.  Additionally, we evaluated the ACR/EULAR 
Boolean criteria, based on 28 and 44 joints, and three alternative definitions of remission: no 
swollen joints (of 44), no ultrasound power Doppler signal and minimal grey scale synovitis 
(sumscore ≤2 of 0-96).[14-16]. For secondary analyses, we defined sustained remission as 
remission at all of the 6, 8, 10 and 12 month visits.  
 
Radiographs and outcomes 
Radiographs (12, 16 and 24 months) were scored by two trained readers, blinded for clinical 
data, in chronological order using the van der Heijde modified Sharp method.[17] We defined 
no radiographic progression as <1 unit change 12-24 months (average score of the readers). 
Good outcome was defined as a combination of no radiographic progression and stable 
physical function assessed by the Patient-Reported Outcome Measurement Information 
System ≥ the median of the general population between 12-24 months,[18] in line with the 
good outcome definition used in the development of the ACR/EULAR remission criteria.[7]  
 
Statistical analysis 
Baseline characteristics were described as proportions (%), means (SD) and medians [25th, 
75th percentile]. Associations between remission status at 6 months and outcomes were 
assessed using logistic regression, with similar analyses for sustained remission. Additionally, 
we calculated sensitivities and specificities, positive and negative likelihood ratios. The 
potential effect modification of biologic therapy on radiographic outcome was assessed by 
including remission status, biologic treatment and interaction terms in separate logistic 
regression models for the two main outcomes. 
In secondary analyses, we calculated the odds ratios of no radiographic progression according 
to state of clinical disease activity (remission, low disease activity, moderate/high disease 
activity) at the 6-month visit, using moderate/high disease activity as reference category.   
Missing radiographs were imputed by inter- or extrapolation if a minimum of 2 radiographs 
were available, whereas missing clinical, laboratory or ultrasound variables at the follow-up 




Of 103 patients, 74% were female, mean (SD) age was 51.4 (12.9) years, disease duration 6.7 
(5.3) months and DAS 3.5 (1.1) (Table S2).  
 
Remission and radiographic progression  
ACR/EULAR Boolean remission based on 44 joints was achieved by 42% of patients at the 6-
month visit, while 59% were in DAS remission and 49% in SDAI remission (Table 1). 
Median radiographic progression 12-24 months was 0.49 [0, 1.03], 71% had no progression. 
Patients in ACR/EULAR Boolean remission (44 joints) had higher odds of no radiographic 
progression from 12-24 months than patients not in remission, as had patients in ultrasound 
remission versus not being in ultrasound remission (Figure 1, Table 1). Patients in remission 
according to the composite indices at 6 months, except for CDAI, had a significantly higher 
odds of no radiographic progression compared to patients with moderate/high disease activity, 
and this was not significant for patients in low disease activity by any of the definitions 
(Table 2). Adjustment for biologic treatment at the 6-month visit (n=12) did not show any 
effect on the association between remission and radiographic progression. Results for patient 
in sustained remission are presented in Table S3.  
 
Remission at 6 months and good outcome 
A good outcome was achieved by 37%. Being in remission at 6 months according to any 
established clinical remission criteria predicted a good outcome, while the ultrasound 
definitions and no swollen joints did not (Figure 1, Table 1). Similar results were found for 




Table 1 The performance of various remission criteria at 6 months for identifying patients without radiographic progression 12-24 months and 
patients with a good combined outcome 12-24 months. Statistically significant findings are shown in bold. N=103. 
 No radiographic progresion Good combined outcome* 




























Clinical outcomes  
   
  
      
DAS 47/61 (77) 26/42 (62) 0.64 0.53 1.38 
(0.91 to 2.10) 
0.67 
(0.42 to 1.05) 
30/61 (49) 8/42 (19) 0.79 0.52 1.66 
(1.22 to 2.24) 
0.40 
(0.21 to 0.78) 
DAS28-ESR 49/64 (77) 24/39 (62) 0.67 0.50 1.34 
(0.91 to 1.99) 
0.66 
(0.40 to 1.07) 
31/64 (48) 7/39 (18) 0.82 0.49 1.61 
(1.21 to 2.13) 
0.37 
(0.18 to 0.76) 
SDAI 39/50 (78) 34/53 (64) 0.53 0.63 1.46 
(0.87 to 2.44) 
0.74 
(0.51 to 1.06) 
29/50 (58) 9/53 (17) 0.76 0.68 2.36 
(1.59 to 3.50) 
0.35 
(0.19 to 0.63) 
CDAI 36/48 (75) 37/55 (67) 0.49 0.60 1.23 
(0.75 to 2.02) 
0.84 
(0.58 to 1.22) 
27/48 (56) 11/55 (20) 0.71 0.68 2.20 
(1.47 to 3.30) 
0.43 
(0.25 to 0.72) 
ACREULAR Boolean 
(44 joints) 
36/43 (84) 37/60 (62) 0.49 0.77 2.11 
(1.06 to 4.21) 
0.66  
(0.49 to 0.89) 
27/43 (63) 11/60 (18) 0.71 0.75 2.89 
(1.80 to 4.62) 
0.38 
(0.23 to 0.64) 
ACREULAR Boolean 
(28 joints) 
36/47 (77) 37/56 (66) 0.49 0.63 1.34 
(0.80 to 2.27) 
0.80 
(0.56 to 1.14) 
28/47 (60) 10/56 (18) 0.74 0.71 2.52 
(1.65 to 3.85) 
0.37 
(0.2 to 0.65) 
No swollen joints  
(44 joints) 
50/67 (75) 23/36 (64) 0.69 0.43 1.21 
(0.85 to 1.71) 
0.73 
(0.43 to 1.24) 
28/67 (42) 10/36 (28) 0.74 0.40 1.23 
(0.93 to 1.62) 
0.66 
(0.36 to 1.21) 
Ultrasound             
Power Doppler=0 
 
64/84 (76) 9/19 (47) 0.88 0.33 1.32 
(1.01 to 1.72) 
0.37 
 (0.17 to 0.82) 
32/84 (38) 6/19 (32) 0.84 0.20 1.05 
(0.88 to 1.26) 
0.79 
(0.33 to 1.90) 
Grey scale score=<2 
 
39/47 (83) 34/56 (61) 0.53 0.73 2.00 
(1.07 to 3.76) 
0.64 
(0.46 to 0.88) 
20/47 (43) 18/56 (32) 0.53 0.59 1.27 
(0.83 to 1.92) 
0.81 
(0.55 to 1.20) 
*Good combined outcome:  A combination of no radiographic progression and stable physical function assessed by the Patient-Reported Outcome Measurement Information System  (PROMIS)  ≥ the median of the general population between 12-24 
months.  
Table 2: Odds ratios of no radiographic progression 12-24 months according to state of 
clinical disease activity composite measures at 6 months. Moderate/high disease activity as 
reference category. Statistically significant findings are shown in bold. N=103. 
  No radiographic progression 12-24 months 
 Classification at 6 months, 
n/N (%) OR (95% CI) P-value 
DAS    
Moderate/ high disease activity 15 (15) ref ref 
Low disease activity 27 (26) 2.71 (0.73 to 10.04) 0.14 
Remission 61 (59) 3.84 (1.18 to 12.45) 0.03 
DAS28-ESR    
Moderate/ high disease activity 19 (18) ref ref 
Low disease activity 20 (19) 3.33 (0.86 to 12.92) 0.08 
Remission 64 (62) 3.63 (1.24 to 10.58) 0.02 
SDAI    
Moderate/ high disease activity 17 (17) ref ref 
Low disease activity 36 (35) 2.02 (0.62 to 6.62) 0.25 
Remission 50 (49) 3.15 (0.98 to 10.09) 0.05 
CDAI    
Moderate/ high disease activity 17 (17) ref ref 
Low disease activity 38 (37) 2.49 (0.75 to 8.22) 0.14 




We found that clinical remission by all established definitions increased the odds of reaching 
a good combined radiographic and physical outcome in early RA, while achieving ultrasound 
remission as well as ACR/EULAR Boolean remission was associated with no radiographic 
progression during the subsequent year. To our knowledge, this is the first study assessing 
both clinical remission and ultrasound remission with regards to future joint damage and good 
physical function in patients treated according to current recommendations.[1, 2]  
EULAR recommends achievement of remission within 6 months in early RA.[1, 2] In our 
study, a good combined outcome was predicted by remission according to any assessed 
clinical composite score. In addition to the two ultrasound remission definitions, only 
ACR/EULAR Boolean remission at six months, with assessment of 44 joints, predicted no 
radiographic progression when comparing patients in remission to all patients not in 
remission. These findings support ACR/EULAR Boolean remission as the preferred 
definition of remission in early RA,[1] but also underline previous publications 
recommending inclusion of the feet when assessing remission.[7, 19] When assessing 
categories of disease activity, low disease activity at 6 months was less associated with no 
radiographic progression than achievement of remission by this point. This adds validity to 
the choice of remission as the preferred treatment target in early RA.[1, 2]  
Good physical function is important to patients. We found that being in ultrasound remission 
did not capture the functional aspects of the disease as well as the clinical criteria. Thus, our 
data support clinical definitions of remission when aiming for a good combined outcome, 
although the data suggest limited specificity and sensitivity for all remission definitions. This 
is in line with the recent findings that targeting ultrasound remission is not superior to 
targeting clinical remission or low disease activity.[14, 20] However, the importance of being 
in ultrasound remission on other patient related outcomes, such as pain, needs to be further 
explored. In some cases, components of the clinical disease activity measures might be 
influenced by non-RA-related factors,[2] and in such settings ultrasonography might be 
suitable to help guide treatment decisions to prevent radiographic progression.  
A limitation of our study is the overall low radiographic progression, which makes it difficult 
to study the association between remission and future joint damage. Thus, the absence of 
significant associations between sustained clinical remission and radiographic progression 
may be attributed to the low overall radiographic progression. This has also been proposed as 
a possible explanation in the COBRA-light trial which demonstrated that remission was 
associated with a good functional outcome, but not predictive of absent radiographic 
progression.[21] The low rate of radiographic progression reflects RA management when 
applying modern treatment strategies. The results are strengthened by the broad inclusion 
criteria compared to industry-sponsored pharmaceutical trials, capturing a broad range of 
early RA patients, and the opportunity to assess ultrasound remission. However, the 
generalizability of the findings to other clinical settings, with different treat-to-target 
strategies, and to other populations such as established RA, is unknown. 
In conclusion, absence of ultrasound inflammation was associated with no subsequent 
radiographic progression, while being in ACR/EULAR Boolean remission after six months of 
targeted therapy increases both the odds of no radiographic progression and a good outcome. 
Our results support current recommendations stating that ACR/EULAR remission including 
assessment of the feet should be the preferred treatment target in early RA, and that low 
disease activity is a less preferred target.    
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Tabell S1 Treatment algorithm  
Visit 
(months) 
Treatment if no response (if response continue treatment at present step) 
1 (0) A. Monotherapy* + Prednisolone: 
1. Methotrexate 15 mg/week, increase by 2.5 mg every 2nd week to target dose 20 mg/week, i.e. week 1+2 15mg, week 3+4
17.5 mg, 
week 5-8 20 mg (optional reduced dosage starting scheme for patients at risk for side effects: week 1 10 mg, week 2 
12.5mg, week 3 15 mg, week 4 17.5mg, week 5-8 20 mg) 
2. Concomitant folic acid 5 mg/week (1mg 5/7 days or 5 mg x 1/week) 
3. Prednisolone 15 mg week 1, 10 mg week 2, 7.5 mg week 3, 5 mg week 4+5, 2.5 mg week 6+7 
4. Calcium supplement 1000mg x 1 (while on prednisolone) 2 (1) A. Monitor start-up regimen (no chang s in medication allowed unless due to AE)* 
Joint injections allowed as indicated according to treatment arm. 
3 (2) A. Optimize monotherapy* 
Increase Methotrexate to 25-30 mg/week 
Or increase SSZ/HCL/leflunomide dose 
4 (3) A. Monitor start-up regimen (no changes in medication allowed unless due to AE)* 
Joint injections allowed as indicated according to treatment arm. 
5 (4) B. Triple combination therapy (or other combination therapy if MTX not tolerated):† 
1. Add salazopyrine, step up over 4 weeks to 500mg 2 x 2 and 
2. Add hydroxychlorochine 200mg 1 x 2 
6 (6) B. Optimize triple combination therapy:† 
Add Prednisolone 7.5 mg 1 x 1 
7 (8) C. DMARD‡ and 1st biologic:∫ 
1. Highest tolerable dose MTX* and 
2. Add 1st biologic (according to current Norwegian guidelines) 
*Or SSZ/HCL/leflunomide if MTX not tolerated 
8 (10) C. DMARD and 1st biologic: 
Adjust dose/interval of 1st biologic 
9 (12) D. DMARD‡ and 2nd biologic: 
Switch to 2nd biologic (according to current Norwegian guidelines) 
10 (14) D. DMARD‡ and 2nd biologic: 
Adjust dose/interval of 2nd biologic 
11 (16) E. DMARD‡ and 3rd biologic: 
Switch to 3rd biologic (according to current Norwegian guidelines) 
12 (20) E. Optimize DMARD and 3rd biologic plus prednisolone: 
Adjust dose/interval of 3rd biologic and/or add prednisolone 7.5mg 
13 (24) F. Continue medication according to standard clinical care 
 
* If MTX is not tolerated, switch to subcutaneous methotrexate), then continue according to scheme. In case of AE or not 
tolerated even in low dose subcutaneous, switch to salazopyrine or hydroxychlorochine monotherapy (standard dosage) 
if low disease activity, or leflunomide 20 mg in case of moderate or high disease activity (loading dose 40mg x 1 for 3 
days, then 20 mg per day). 
† In patients with high disease activity and risk factors for progressive joint destruction ( ACPA or RF-positive and either 
erosions on CR or baseline RAMRIS bone marrow edema score >2) a rescue option is available which includes moving to 
the next step, i.e. introduce 1st 
biologic (treatment C at visit #5, without prescribing treatment B). 
‡ In case of no tolerance for any conventional DMARD, this can be omitted if the biologic drug chosen has indication for 
monotherapy (e.g. tociluzimab). 
∫ Requirement for adding biologic: There must be objective signs of ongoing inflammation, i.e. either elevated ESR/CRP 
(>UNL, and not due to other disease/infection) or SJC>1 (or PD score >1 in US arm). 
 
  
Table S2 Baseline characteristics.  
Values are mean (SD) unless otherwise stated.  
Variables Ultrasound tight 
control strategy 
N=103 
Female, n (%)  76 (73.8) 
Age, years 51.4 (12.9) 
Smoker ever, n (%) 66 (64.1) 
Disease duration, months 6.7 (5.3) 
Symptom duration < 3 months at DMARD initiation, n (%) 29 (28.2) 
Positive for ACPA, n (%) 81 (78.6) 
Positive for RF, n (%)  64 (62) 
Body mass index (kg/m2) 25.6 (3.9) 
Ritchie articular index (0-78) 8.5 (6.7) 
Swollen joint count (0-44) 10.8 (7.1) 
Erythrocyte sedimentation rate, mm/hr (1-140) 23.4 (18.0) 
C reactive protein, mg/L 14.3 (19.7)  
Disease activity score 3.5 (1.1) 
Ultrasound grey scale score (0-96) 20.4 (12.3) 
Ultrasound power Doppler score (0-96) 9.4 (8.2) 
Patient’s global assessments of disease activity, VAS (0-100mm) 51.5 (24.9) 
Physician’s global assessments of disease activity, VAS (0-100mm) 40.0 (19.8) 
van der Heijde-modified Sharp score (0-448), median [25th, 75th] 
Erosion score 
Joint space narrowing 
4 [1.5, 8] 
3 [1, 4] 
1 [0, 3] 
PROMIS Physical Function (12.1-62.5) 39.1 (9.0) 
DMARD=Disease modifying anti-rheumatic drug. ACPA=Anti-cyclic citrullinated peptides. RF=Rheumatoid factor.  
VAS=Visual analogue scale. PROMIS=Patient reported Outcome Measurement Information Score Short Form v1.0 – 
Physical Function 20a (reported as T-scores).  
  
Table S3 The performance of sustained remission 6-12 months for identification of patients without radiographic progression 12-24 months, and 
with a good combined outcome 12-24 months. Significant values in bold.  
 No radiographic progression Good combined outcome* 
Prevalence of no 































Clinical outcomes  
   
  
      
DAS 33/45 (73) 40/58 (69) 0.45 0.60 1.13 
(0.68 to 1.87) 
0.91 
(0.64 to 1.31) 
27/45 (60) 11/58 (19) 0.71 0.72 2.57 
(1.65 to 3.99) 
0.40 
(0.24 to 0.67) 
DAS28-ESR 36/47 (77) 37/56 (66) 0.49 0.63 1.34 
(0.80 to 2.27) 
0.80 
(0.56 to 1.14) 
28/47 (60) 10/56 (18) 0.74 0.71 2.52 
(1.65 to 3.85) 
0.37 
(0.21 to 0.65) 
SDAI 24/34 (71) 49/69 (71) 0.33 0.67 0.99 
(0.54 to 1.80) 
1.01 
(0.75 to 1.36) 
21/34 (62) 17/69 (25) 0.55 0.80 2.76 
(1.57 to 4.86) 
0.56 
(0.38 to 0.81) 
CDAI 21/31 (68) 52/72 (72) 0.29 0.67 0.86 
(0.46 to 1.61) 
1.07 
(0.80 to 1.43) 
18/31 (58) 20/72 (28) 0.47 0.80 2.37 
(1.31 to 4.27) 
0.66 
(0.48 to 0.91) 
ACREULAR Boolean 
(44 joints) 
17/22 (77) 56/81 (69) 0.23 0.83 1.40 
(0.57 to 3.44) 
0.92 
(0.75 to 1.13) 
17/22 (77) 21/81 (26) 0.44 0.92 5.82 
(2.33 to 14.5) 
0.60 
(0.45 to 0.80) 
ACREULAR Boolean 
(28 joints) 
20/27 (74) 53/76 (70) 0.27 0.77 1.17 
(0.56 to 2.48) 
0.95 
(0.74 to 1.21) 
18/27 (67) 20/76 (26) 0.47 0.86 3.42 
(1.71 to 6.84) 
0.61 
(0.44 to 0.84) 
No swollen joints  
(44 joints) 
35/45 (78) 38/58 (66) 0.58 0.67 1.44 
(0.82 to 2.52) 
0.78 
(0.56 to 1.09) 
22/45 (49) 16/58 (28) 0.58 0.65 1.64 
(1.07 to 2.51) 
0.65 
(0.43 to 0.99) 
Ultrasound             
Power Doppler=0 
 
48/59 (81) 25/44 (57) 0.66 0.63 1.79 
(1.09 to 2.95) 
0.54 
(0.36 to 0.82) 
26/59 (44) 12/44 (27) 0.68 0.49 1.35 
(0.98 to 1.86) 
0.64 
(0.38 to 1.09) 
Grey scale score=<2 19/21 (90) 54/82 (66) 0.26 0.93 3.90 
(0.97 to 15.73) 
0.79 
(0.67 to 0.94) 
10/21 (48) 28/82 (34) 0.26 0.83 1.56 
(0.73 to 3.32) 
0.89 
(0.71 to 1.10) 
*Good combined outcome:  A combination of no radiographic progression and stable physical function assessed by the Patient-Reported Outcome Measurement Information System  (PROMIS)  ≥ the median of the general population between 12-24 
months.  
 
 
